MCL1 and ovarian neoplasm: However, in our two PDTO models, the belinostat/AMG 176 combination displayed effective anticancer activity, supporting the concept that Mcl‐1 inhibition would represent a promising strategy to sensitize ovarian tumors to belinostat.